https://scholars.lib.ntu.edu.tw/handle/123456789/514557
Title: | Clinical impact of [18F]FDG-PET in patients with suspected recurrent breast cancer based on asymptomatically elevated tumor marker serum levels: A preliminary report | Authors: | Liu C.-S. Shen Y.-Y. Lin C.-C. RUOH-FANG YEN Kao C.-H. |
Issue Date: | 2002 | Journal Volume: | 32 | Journal Issue: | 7 | Start page/Pages: | 244-247 | Source: | Japanese Journal of Clinical Oncology | Abstract: | Objective: To evaluate retrospectively the impact of [18F]fluorodeoxyglucose positron emission tomography (FDG-PET) on the detection of recurrent breast cancer based on asymptomatically elevated tumor markers levels. Methods: Whole-body FDG-PET was performed in 30 patients with suspected recurrent breast cancer and asymptomatic tumor marker increase but negative or equivocal other imaging modality results. A blood sample was drawn in each case for marker assay (CA 15-3 and CEA) on the same day as the FDG-PET. All of these 30 asymptomatic patients had either CA l5-3 >32 U/ml or CEA >5 ng/ml. The final diagnosis of recurrent breast cancer was established by operation/biopsy histopathological findings or clinical follow-up for >1 year by additional morphological imaging techniques. Results: Among the 30 patients, the final diagnosis of recurrent breast cancer was established in 38 sites in 28 patients. FDG-PET accurately detected 35/38 sites in 25/28 patients with recurrence. The diagnostic sensitivity and accuracy of FDG-PET in patients with suspected recurrent breast cancer and asymptomatically elevated tumor markers were 96 and 90%, respectively. Conclusions: FDG-PET is a useful technique for detecting recurrent breast cancer suspected from asymptomatically elevated tumor markers levels and has an important clinical impact on the management of these patients. ? 2002 Foundation for Promotion of Cancer Research. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/514557 | ISSN: | 0368-2811 | DOI: | 10.1093/jjco/hyf052 | SDG/Keyword: | CA 15-3 antigen; carcinoembryonic antigen; fluorodeoxyglucose f 18; medronate technetium tc 99m; tumor marker; diagnostic agent; fluorodeoxyglucose f 18; tumor marker; adult; article; blood sampling; breast cancer; breast surgery; cancer localization; clinical article; controlled study; diagnostic accuracy; diagnostic imaging; female; follow up; histopathology; human; human tissue; morphometrics; patient care; positron emission tomography; protein blotting; recurrent cancer; sensitivity analysis; whole body tomography; aged; breast tumor; computer assisted emission tomography; evaluation; middle aged; retrospective study; tumor recurrence; Adult; Aged; Breast Neoplasms; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Tomography, Emission-Computed; Tumor Markers, Biological [SDGs]SDG3 |
Appears in Collections: | 醫學院附設醫院 (臺大醫院) |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.